Literature DB >> 16216978

Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice.

Ana Kilic1, Ana Velic, León J De Windt, Larissa Fabritz, Melanie Voss, Danuta Mitko, Melanie Zwiener, Hideo A Baba, Martin van Eickels, Eberhard Schlatter, Michaela Kuhn.   

Abstract

BACKGROUND: Atrial natriuretic peptide (ANP), through its guanylyl cyclase-A (GC-A) receptor, not only is critically involved in the endocrine regulation of arterial blood pressure but also locally moderates cardiomyocyte growth. The mechanisms underlying the antihypertrophic effects of ANP remain largely uncharacterized. We examined the contribution of the Na+/H+ exchanger NHE-1 to cardiac remodeling in GC-A-deficient (GC-A(-/-)) mice. METHODS AND
RESULTS: Fluorometric measurements in isolated adult cardiomyocytes demonstrated that cardiac hypertrophy in GC-A(-/-) mice was associated with enhanced NHE-1 activity, alkalinization of intracellular pH, and increased Ca2+ levels. Chronic treatment of GC-A(-/-) mice with the NHE-1 inhibitor cariporide normalized cardiomyocyte pH and Ca2+ levels and regressed cardiac hypertrophy and fibrosis, despite persistent arterial hypertension. To characterize the molecular pathways driving cardiac hypertrophy in GC-A(-/-) mice, we evaluated the activity of 4 prohypertrophic signaling pathways: the mitogen-activated protein kinases (MAPK), the serine-threonine kinase Akt, calcineurin, and Ca2+/calmodulin-dependent kinase II (CaMKII). The results demonstrate that all 4 pathways were activated in GC-A(-/-) mice, but only CaMKII and Akt activity regressed during reversal of the hypertrophic phenotype by cariporide treatment. In contrast, the MAPK and calcineurin/NFAT signaling pathways remained activated during regression of hypertrophy.
CONCLUSIONS: On the basis of these results, we conclude that the ANP/GC-A system moderates the cardiac growth response to pressure overload by preventing excessive activation of NHE-1 and subsequent increases in cardiomyocyte intracellular pH, Ca2+, and CaMKII as well as Akt activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216978     DOI: 10.1161/CIRCULATIONAHA.105.542209

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

Review 1.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

2.  A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway.

Authors:  Ana Kilic; Venkatesh Rajapurohitam; Sharon M Sandberg; Asad Zeidan; J Craig Hunter; Nazo Said Faruq; Candace Y Lee; John C Burnett; Morris Karmazyn
Journal:  Cardiovasc Res       Date:  2010-08-02       Impact factor: 10.787

Review 3.  Recent insights into cardiac hypertrophy and left ventricular remodeling.

Authors:  Risto Kerkela; Thomas Force
Journal:  Curr Heart Fail Rep       Date:  2006-04

4.  Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.

Authors:  U Hofmann; K Hu; F Walter; N Burkard; G Ertl; J Bauersachs; O Ritter; S Frantz; A Bonz
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Na(+)/H (+) exchanger isoform 1 induced osteopontin expression in cardiomyocytes involves NFAT3/Gata4.

Authors:  Mohamed Mlih; Nabeel Abdulrahman; Alain-Pierre Gadeau; Iman A Mohamed; Maiy Jaballah; Fatima Mraiche
Journal:  Mol Cell Biochem       Date:  2015-03-11       Impact factor: 3.396

6.  Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.

Authors:  Robert Lukowski; Sergei D Rybalkin; Florian Loga; Veronika Leiss; Joseph A Beavo; Franz Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

Review 7.  Regulation of intracellular and mitochondrial sodium in health and disease.

Authors:  Elizabeth Murphy; David A Eisner
Journal:  Circ Res       Date:  2009-02-13       Impact factor: 17.367

8.  Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2.

Authors:  Michael Klaiber; Martin Kruse; Katharina Völker; Juliane Schröter; Robert Feil; Marc Freichel; Andrea Gerling; Susanne Feil; Alexander Dietrich; Juan Eduardo Camacho Londoño; Hideo A Baba; Joel Abramowitz; Lutz Birnbaumer; Josef M Penninger; Olaf Pongs; Michaela Kuhn
Journal:  Basic Res Cardiol       Date:  2010-03-30       Impact factor: 17.165

9.  Homologous desensitization of guanylyl cyclase A, the receptor for atrial natriuretic peptide, is associated with a complex phosphorylation pattern.

Authors:  Juliane Schröter; René P Zahedi; Michael Hartmann; Birgit Gassner; Alexandra Gazinski; Jens Waschke; Albert Sickmann; Michaela Kuhn
Journal:  FEBS J       Date:  2010-04-26       Impact factor: 5.542

Review 10.  Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome.

Authors:  G Martel; P Hamet; Johanne Tremblay
Journal:  Mol Cell Biochem       Date:  2009-11-25       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.